BioSpace News Archive

Dexcom, Inc. announced its strategy to bring Dexcom glucose sensing technology to millions more people around the globe and new Dexcom CGM research featured at the 83rd Scientific Sessions of the American Diabetes Association being held June 23-26 in San Diego.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced plans to advance its investigational drug LX9211 into late-stage development in a clinical program directed towards an application for regulatory approval in diabetic peripheral neuropathic pain, or DPNP.

New research from the National Institutes of Health found that blood glucose levels obtained at childhood examinations predicted future diabetes related complications such as kidney disease and eye disease.

XORTX Therapeutics Inc. would like to remind shareholders that they have until 10:00 a.m. on Monday, June 26, 2023 to vote their shares for the Company’s upcoming annual and special meeting of shareholders to be held on Wednesday, June 28, 2023 at 10:00 a.m.

Carmot Therapeutics, Inc. announced positive results from the following studies: a Phase 1 clinical trial of CT-388 assessing safety, tolerability, pharmacokinetics and pharmacodynamic activity in overweight and obese otherwise healthy participants and a preclinical study in rodent models of type 1 diabetes to support the effects of CT-868 as an adjunct to insulin treatment.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the MiniMed™ 780G system.

Findings from two studies showcase groundbreaking technology and the latest diabetes developments related to glucose control and diabetic retinopathy.

Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced data from its Phase 1b trial for INV-202 to be presented in a poster session at the 83rd American Diabetes Association Scientific Sessions (ADA) in San Diego.

Eli Lilly and Company announced new phase 2 data for orforglipron, its first nonpeptide oral glucagon-like peptide-1 receptor agonist being studied for chronic weight management in participants with obesity or overweighti.

Sciwind Biosciences Co., Ltd. today announced that the company will present positive results from clinical studies of ecnoglutide at the 83rd American Diabetes Association (ADA) conference.